Dow Jones received a payment from EQS/DGAP to publish this press release.
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability
19-Feb-2019 / 07:34 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Sartorius Stedim Biotech: Information on Document Availability
Aubagne, February 19, 2019 - Sartorius Stedim Biotech Group's Annual Report
2018 is now available at
https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biote
ch-sa-investor-relations [1]
It contains the following information:
- Business development for fiscal 2018 and the 2019 forecast for the Sartorius
Stedim Biotech Group
- Consolidated financial statements for the year ended December 31, 2018
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the
biopharmaceutical industry. As a total solutions provider, the company helps
its customers to manufacture biotech medications safely, rapidly and
economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is
quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D
sites in Europe, North America and Asia and an international network of sales
companies, Sartorius Stedim Biotech has a global reach. The Group has been
annually growing by double digits on average and has been regularly expanding
its portfolio by acquisitions of complementary technologies. In 2018, the
company employed approx. 5,600 people, and earned sales revenue of EUR1,212.2
million.
______________________________________________________________________________
____________
Contact
Petra Kirchhoff; Head of Corporate Communications and Investor Relations
Phone: +49(0)551.308.1686; petra.kirchhoff@sartorius.com
Regulatory filing PDF file
Document title: Information on Document Availability
Document: http://n.eqs.com/c/fncls.ssp?u=RDWTLFNDGL [2]
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: info@sartorius-stedim.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext Ticker: DIM
AMF Category: Terms of availability of the annual financial report
End of Announcement EQS News Service
777225 19-Feb-2019 CET/CEST
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=6c2d28e59a2bbaf6c800dee64704a280&application_id=777225&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=b6e4b18e7edd23db0153770a8f66877e&application_id=777225&site_id=vwd&application_name=news
(END) Dow Jones Newswires
February 19, 2019 01:34 ET (06:34 GMT)
